The long-time biases held by investors in potentially high-value diagnostics persist: that companies don’t have all that much pricing power; and those that succeed in technology development often balk – certainly early on – at investing in the kinds of studies that would prove the technology should be practice-changing. Little happened to alter that view during the year.
If anything, the biggest newsmaker in 2014 heightened concerns over the business model. The US Food and Drug Administration finally took steps toward establishing an oversight framework for the regulation...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?